METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
First Claim
1. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides, wherein said oligonucleotide is complementary along its entire length to a sequence within the human dystrophin exon 45 pre-mRNA, wherein said sequence is also complementary to at least 22 nucleotides of a sequence consisting of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID NO;
3).
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
3 Citations
76 Claims
-
1. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides, wherein said oligonucleotide is complementary along its entire length to a sequence within the human dystrophin exon 45 pre-mRNA, wherein said sequence is also complementary to at least 22 nucleotides of a sequence consisting of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID NO;
3). - View Dependent Claims (2, 3, 8, 9, 10, 11, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 32, 43, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 67, 69, 70, 71, 72, 73, 74, 75)
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
4. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides, wherein said oligonucleotide is complementary along its entire length to a sequence within the human dystrophin exon 45 pre-mRNA, wherein said sequence is also complementary to at least 22 nucleotides of a sequence consisting of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID NO;
3), wherein the oligonucleotide comprises a modified base, and/or a modified sugar moiety, and/or a modified internucleoside linkage. - View Dependent Claims (5, 12, 13, 14, 25, 26, 27, 28, 29, 31, 63, 64, 68, 76)
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
6. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides, wherein said oligonucleotide is complementary along its entire length to a sequence within the human dystrophin exon 45 pre-mRNA, wherein said sequence is also complementary to at least 22 nucleotides of a sequence consisting of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID NO;
3), wherein the oligonucleotide comprises a phosphorodiamidate morpholino oligomer (PMO), peptide nucleic acid, and/or locked nucleic acid.
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
7. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides, wherein said oligonucleotide is capable of binding to a continuous stretch of nucleotides within the human dystrophin exon 45 pre-mRNA, and wherein PS220 (5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
) (SEQ ID NO;
3) is capable of binding to said continuous stretch of nucleotides.
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
15. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides, wherein said oligonucleotide is complementary along its entire length to a sequence in part of the human dystrophin exon 45 pre-mRNA, wherein said sequence is complementary to at least 22 nucleotides of a sequence consisting of 5′
- UUUGCCGCUGCCCAAUGCCAUCCUG 3′
(SEQ ID NO;
3);
wherein each sugar moiety of the oligonucleotide is 2′
-O-methyl substituted and each of the internucleoside linkages present in the oligonucleotide comprises a phosphorothioate moiety.
- UUUGCCGCUGCCCAAUGCCAUCCUG 3′
-
33. An oligomer for ameliorating DMD, the oligomer consisting of 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides, comprising at least 22 nucleotides of the base sequence of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID;
NO;
3);
wherein the bases of the oligomer are selected from the group consisting of;
adenine, cytosine, guanine, thymine and uracil; and
wherein the molecule can bind to a target site to cause exon skipping in an exon of the dystrophin gene. - View Dependent Claims (34, 35, 36)
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
37. An oligomer for alleviating DMD, the oligomer consisting of 25 nucleotides, and consisting of the sequence 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID;
NO;
3);
wherein the molecule can bind to a target site to cause exon skipping in an exon of the dystrophin gene.
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
38. An isolated antisense oligomer whose base sequence consists of the base sequence of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID;
NO;
3). - View Dependent Claims (40, 41, 42)
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
39. An isolated antisense oligomer consisting of 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides comprising at least 22 nucleotides of the base sequence of 5′
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
(SEQ ID;
NO;
3).
- -UUUGCCGCUGCCCAAUGCCAUCCUG-3′
-
44. An isolated antisense oligonucleotide consisting of 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides, wherein said oligonucleotide is complementary to at least 22 nucleotides of a sequence consisting of 5′
- UUUGCCGCUGCCCAAUGCCAUCCUG 3′
(SEQ ID NO;
3). - View Dependent Claims (46, 47)
- UUUGCCGCUGCCCAAUGCCAUCCUG 3′
-
45. An isolated antisense oligonucleotide, consisting of 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides, wherein said oligonucleotide is complementary to at least 22 nucleotides of a sequence consisting of 5′
- UUUGCCGCUGCCCAAUGCCAUCCUG 3′
(SEQ ID NO;
3);
wherein said oligonucleotide comprises at least one 2′
-O-methyl substituted sugar moiety and at least one internucleoside linkage.
- UUUGCCGCUGCCCAAUGCCAUCCUG 3′
-
49. A method for inducing and/or promoting the skipping of exon 45 of the human dystrophin pre-mRNA, said method comprising:
providing an oligonucleotide of 21 to 50 nucleotides in length to a cell, wherein said oligonucleotide comprises a nucleotide sequence which is complementary to a target sequence of exon 45 of the human dystrophin pre-mRNA, wherein said target sequence comprises a nucleotide sequence that is complementary to the sequence UUUGCCGCUGCCCAAUGCCAUCCUG (SEQ ID NO;
3) and wherein said oligonucleotide induces skipping of said exon in the cell.
-
50. A method for treating Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) in a patient by inducing the skipping of exon 45 of the human dystrophin pre-mRNA, said method comprising:
providing an oligonucleotide of 21 to 50 nucleotides in length to a cell, wherein said oligonucleotide comprises a nucleotide sequence which is complementary to a target sequence of exon 45 of the human dystrophin pre-mRNA, wherein said target sequence comprises a nucleotide sequence that is complementary to the sequence UUUGCCGCUGCCCAAUGCCAUCCUG (SEQ ID NO;
3) and wherein said oligonucleotide induces skipping of said exon in the cell.
Specification